State-of-the-art automated 3D imaging workcell
The Organoid Innovation Center at Molecular Devices combines cutting-edge technologies with novel research methods to address key challenges of scaling complex 3D biological models.
The collaborative space brings customers and researchers into the lab to test automated workflows for organoid culturing and screening, with guidance from in-house scientists.Learn more
3D biology is an emerging field revolutionizing the way scientists screen new drugs and understand diseases.
3D cell models like organoids have a unique makeup that offers a step-change in predicting human responses to novel treatments. Their increased physiological relevance leads to more accurate indications of a therapeutic’s efficacy in the pre-clinical phase. This allows for the weeding out of toxic, ineffective compounds to make space for those with healing power earlier in the drug discovery process.Learn more
The addition of our colony picker platform expands the Center’s state-of-the-art methods and technologies to include automated workflows for synthetic biology, antibody discovery, and cell line development.
And, with the recent launch of CloneSelect® Imager FL with multi-channel fluorescence for day zero monoclonality verification and confirmation of CRISPR edits, provides a wide range of cell and gene therapy applications.Learn more
From our PhD-level technical support staff to our expert-trained and certified field service engineers, our Global Professional Services teams guide scientists through customized automation solutions that are uniquely designed to meet the specific needs of your assay, method, or protocol.
We offer a highly consultative approach when automating high-throughput plate-based, cellular screening, and clone screening assays with customized, automated labware, robotic solutions, and intuitive software.Learn more
Proprietary patient-derived organoid technology
“Molecular Devices has the capability, reputation, reach, and resources to ensure that the Cellesce technology can be further developed, and used to its full potential. We’re excited to bring our domain expertise and intellectual property to Molecular Devices, together maximizing impact for customers in revolutionizing drug discovery and unlocking the full potential of human-relevant 3D biology research.”
– Vicky Marsh-Durban, CEO of Cellesce